Merseburger Axel S, Hennenlotter Joerg, Kuehs Ursula, Simon Perikles, Kruck Stephan, Koch Eva, Stenzl Arnulf, Kuczyk Markus A
Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.
Urol Int. 2008;80(4):372-7. doi: 10.1159/000132694. Epub 2008 Jun 27.
The epidermal growth factor receptor- (EGFR) activated phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt) pathway is associated with tumorigenesis and progression. The aims of the present study were to determine the expression patterns of Akt pathway parameters PI3K, phosphatase and tensin homolog (PTEN), phosphor-Akt (p-Akt) and their combination, for their possible prognostic value in renal cell carcinoma (RCC). PTEN dephosphorylates the liquid product of PI3K.
Tumor samples from 176 RCC patients were investigated for PTEN, p-Akt and PI3K expression by immunohistochemistry. Expression levels were correlated to clinical variables and postoperative outcome by uni- and multivariate statistical analysis.
The various expression levels within the tumor samples were independent of histological grade and tumor stage, due to different levels of activation of the PI3K/p-Akt pathway. The activation of PI3K protein was found to be significantly associated with reduced survival times (p = 0.0304, multivariate analysis). Analysis of combined biomarker expressions showed that decreased long-term survival was correlated with PTEN low/p-Akt high expression (p < 0.05).
Activation of the PI3K pathway is significantly associated with adverse clinical outcome in RCC. Analysis of biomarker combinations might identify high-risk patients and a subsequent need to adapt treatment modalities. Molecular pathways regulating PI3K activation appear to be promising targets for drug development in the clinical management of RCC patients.
表皮生长因子受体(EGFR)激活的磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(PKB/Akt)信号通路与肿瘤的发生和进展相关。本研究旨在确定Akt信号通路参数PI3K、磷酸酶和张力蛋白同源物(PTEN)、磷酸化Akt(p-Akt)及其组合的表达模式,以探讨其在肾细胞癌(RCC)中的潜在预后价值。PTEN可使PI3K的产物去磷酸化。
采用免疫组织化学法检测176例RCC患者肿瘤样本中PTEN、p-Akt和PI3K的表达。通过单因素和多因素统计分析,将表达水平与临床变量和术后结果进行关联。
由于PI3K/p-Akt信号通路的激活水平不同,肿瘤样本中的各种表达水平与组织学分级和肿瘤分期无关。发现PI3K蛋白的激活与生存时间缩短显著相关(多因素分析,p = 0.0304)。联合生物标志物表达分析表明,长期生存率降低与PTEN低表达/p-Akt高表达相关(p < 0.05)。
PI3K信号通路的激活与RCC不良临床预后显著相关。生物标志物组合分析可能有助于识别高危患者,并确定后续调整治疗方式的必要性。调节PI3K激活的分子通路似乎是RCC患者临床治疗中药物研发的有前景的靶点。